logo.png
Allarity Therapeutics and Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven
July 26, 2021 02:30 ET | Allarity Therapeutics A/S
Lantern will reacquire global rights to Irofulven and assume full authority to manage and guide future clinical and commercial development of the program Press release Hørsholm, Denmark and...